Latest Administration News

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

Field Solutions Group has executed a binding agreement to sell its TasmaNet business to Comms Group Ltd as part of its receivership process, with further asset sales underway.

The Finnish Government’s proposed amendments to the Mining Act could resolve licensing uncertainties for Latitude 66’s KSB Project, even as key mining rights expire following a court decision.

Comms Group Limited announces a strategic $10 million acquisition of TasmaNet and select assets from Field Solutions Holdings, alongside a $7 million capital raise, targeting a proforma FY25 revenue of approximately $75 million.

Classic Minerals Limited has announced the resignation of CEO Dean Goodwin, effective April 7, 2025, with Chair John Lester stepping in as interim leader. The delayed disclosure raises questions about governance timing.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

NRW Holdings faces a significant threat to its $113.3 million secured debt after the South Australian Government proposed legislation that could invalidate key lease agreements underpinning its security interests in Whyalla Ports.

EDU Holdings Limited plans to voluntarily delist from the ASX, citing low share liquidity and regulatory uncertainty in the international student market. The company proposes a substantial buy-back offer to provide shareholders with an exit opportunity ahead of delisting.

NEXION Group has entered a non-binding agreement to sell its Perth data centre subsidiary to Canadian firm Carrier Connect Data Solutions for AUD 2.5 million, aiming to strengthen its balance sheet.

Dropsuite Limited’s shares are suspended from ASX trading following Federal Court approval of its acquisition by NinjaOne Australia, marking a pivotal step in the company’s transition.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.